Annual Media Conference
30 January, 2008

William M. Burns, CEO Pharmaceuticals Division

2007: Highlights in Pharma

Double-digit growth in sales and profits

- Pharma sales (+11% in LC), Roche Pharma Q4: +14% (excl. Tamiflu)
- Operating profit margin improved by 3.8% pts to 35.5%

Major progress for key marketed assets

- Avastin launched in advanced breast and lung cancer (EU), approved in renal cell carcinoma (EU)
- Approval of Avastin in 1st and later lines mCRC (EU) – not restricted by chemo choice
- Mircera launched in EU

Major pipeline progress

- Actemra filed in EU / US
- Ocrelizumab moved into phase III in lupus (SLE and LN), and into phase II in MS
- Pertuzumab phase III in metastatic breast cancer starting soon
- CETP inhibitor: decision to move into phase III
- GLP-1: phase II data encouraging

Pharma continues to significantly outgrow the market

CHF 3.5 billion additional organic sales

Sales CHF m	2006	2007	% change in CHF	% change in local	USD growth
Roche Pharma	20,666	22,970	11	9	16
Genentech	9,125	10,414	14	19	19
Chugai	3,503	3,399	-3	3	1
Pharmaceuticals	**33,294**	**36,783**	**10**	**11**	**15**

Growth in %	incl. Tamiflu[1] H1/07	incl. Tamiflu[1] H2/07	incl. Tamiflu[1] 2007	excl. Tamiflu[1] H1/07	excl. Tamiflu[1] H2/07	excl. Tamiflu[1] 2007
Pharmaceuticals Division	**18**	**6**	**11**	**15**	**11**	**13**
Roche Pharma	16	4	9	12	12	12
Genentech	28	12	19	28	12	19
Chugai	7	-1	3	-1	4	1

1 Government and corporate pandemic

2007: Pharma operating performance

Operating profit growth twice sales

	2007 CHF m	2007 % sales	
Sales	36,783	100.0	+3,489
Royalties & other op inc	2,057	5.6	+848
Cost of sales	-9,502	-25.8	-470
M & D	-7,018	-19.1	-159
R & D	-7,598	-20.6	-1,008
G & A	-1,680	-4.6	-203
Operating profit	13,042	35.5	+2,497

2007 vs. 2006 local growth



[1] Manufacturing Costs of goods sold & period costs

Review of core assets by therapeutic area

Pipeline, Outlook and future catalysts

Roche Oncology: Strongest growing franchise

Avastin: Best growing oncology brand ever



Oncology: key brands

Existing and new indications fuelling growth

Major brands (CHF bn)



MabThera/Rituxan: Growth mainly from use following 1st l. in iNHL & RA (global RA sales: approx. CHF 500 m)

Herceptin: Penetration in adj BC now 70% in top 5 EU and ~75% in US – still considerably lower in RoW

Avastin: US: Good uptake in NSCLC; EU: Strong growth in mCRC – promising launches in NSCLC, mBC

Xeloda: Increased use in adj CC and mCRC (both EU and US) continues to drive growth

Tarceva: Strong growth in Europe (NSCLC), EU approval for pancreatic cancer received early 2007

Oncology in 2008
Preparing for new market opportunities

Breast cancer (BC)

- Phase III data (AVADO, RIBBON-1) to broaden Avastin label for combination with all major chemos
- HER2+ mBC
  - phase III for pertuzumab to start in Q1
  - opted-in to trastuzumab-DM1
- Avastin adjuvant trials started: Large potential new market opportunity

Metastatic colorectal cancer (mCRC)

- Launch of Avastin and Xeloda in 1st and later lines – not restricted by chemo choice (incl. oxaliplatin) (EU)

Chronic lymphocytic leukemia (CLL)

- Positive data in 1st line - MabThera to enter a new market in Europe

Inflammation/Autoimmune/Transplantation

MabThera RA launch successful



2007

Overall franchise growing +11%

MabThera RA sales ~CHF ½ billion

Rheumatoid Arthritis

- MabThera: Launched (TNF failures)
- Actemra: Filed in EU and US (RA)
- Ocrelizumab: Phase III initiated

Lupus

- Ocrelizumab: Phase III initiated

Multiple Sclerosis

- MabThera: Positive phase II (RRMS)
- Ocrelizumab: Phase II decision taken

Inflammation/Autoimmune in 2008
Major market opportunities in focus

Rheumatoid Arthritis

- MabThera for DMARD-IRs (1st line biologic) expect data and filing
- Actemra: regulatory approval expected (first in US)

Multiple Sclerosis

- Phase II/III data for MabThera in PPMS in H1 2008

Lupus

- Phase II/III data for MabThera in SLE in H1 2008

Virology
Building on our HCV franchise

Major brands (CHF bn)



Pandemic sales of CHF 1.9 bn (90% of total sales); CHF 100-150 million expected in ’08 pandemic sales

Growth ex-US more than offsets US market decline; Japanese Copegus combo launch successful

Growth driven by increased use in transplant and HIV/AIDS indications

Steady growth in EU, decline in US

Slight increase due to Japan, flat in EU/RoW

Growth driven by Invirase 500mg

Building new assets in HCV – early but promising data with polymerase and protease inhibitors

Metabolism/Diabetes in 2008
Committed to become a major player

CETP Inhibitor to move into phase III

- Safety data to be presented at major medical meetings

GLP-1 phase II data available

- Decision for phase III to be taken in H1 2008
- Publication planned for 2008

Phase II data for DPP-IV (3) and PPARαγ expected

- Looking for a differentiated profile (e.g. weight reduction for DPP-IV)
- Go/no-go decisions for phase III trials to be taken this year

Review of core assets by therapeutic area

Pipeline, Outlook and future catalysts

Major phase III commitments – large investments

Additional large phase III trials started or starting soon



Pharmaceuticals objectives for 2008

A rich clinical news flow ahead

Major clinical data

Compound	Phase	Indication / data	Timing
Avastin	III	mBC (AVADO)	H1 2008
Avastin	III	mBC (RIBBON-1)	H2 2008
Avastin+Tarceva	III	2nd line NSCLC (BETA lung) interim	Event-driven
Tarceva	III	1st line NSCLC (SATURN)	H2 2008
MabThera	III	RA, DMARD-IR	Q1 2008
MabThera	III	SLE (EXPLORER)	H1 2008
MabThera	III	PPMS (OLYPMUS)	H1 2008
MabThera	III	CLL 1^{st} line ph. III data interim	Q1 2008
MabThera	III	CLL relapsed ph. III data interim	Event-driven
Xeloda	III	Adjuvant CC (NO16968) interim	Event-driven
Actemra	III	RA (AMBITION, RADIATE) full data	2008
GLP-1	IIb	Type 2 diabetes full data	2008
DPP-IV	II	Type 2 diabetes	H2 2008

Filings

Compound	Indication
Avastin	mBC (AVADO)
Avastin+Tarceva	NSCLC 2nd line (BETA lung)
MabThera	RA, DMARD IR

Divisional sales growth

Above-market excluding pandemic Tamiflu

barring unforeseen events

Roche

We Innovate Healthcare